CDMO will be providing high-quality lentiviral vectors for CAR-T therapies.
Vector BioMed, a contract development and manufacturing organization (CDMO), has officially launched. The company’s main efforts will be toward providing access to high-quality lentiviral vectors for pre-clinical development, clinical trials, and commercialization.
The commercial success of chimeric antigen receptor T-cell (CAR-T) cell therapy in cancer and hematopoietic stem cells for genetic diseases has created a demand for manufacturing capacity and reagents, especially for custom lentiviral vectors, which is considered a main method for delivery of genes into therapeutic cellular populations.
As previously alluded to, the organization aims to address the industry's vector supply bottleneck by providing lentiviral vectors at scale, while also offering turnkey solutions for vector design and optimization, pre-clinical manufacturing, and good manufacturing practice (GMP) manufacturing, along with other support services. Essentially, the company is aiming to provide algorithm-optimized vectors that can enable superior vector titer and function, and a platform serum-free suspension vector manufacturing process.
Read more about the launch here.